Therapeutics: Tumor necrosis factor receptor superfamily member 11a (RANK; TNFRSF11A; CD265); receptor activator of NF-κB ligand (RANKL; TNFSF11); breast cancer

Cancer

INDICATION: Breast cancer

Patient sample and mouse studies suggest inhibiting RANKL could help treat BRCA1-mutant breast cancer. In tissue samples from breast cancer patients, levels of the RANKL receptor RANK

Read the full 295 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE